TPST — Tempest Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1544227 ·
Last close
$1.26
Market Cap
$18.66M
52W High
$2.46
52W Low
$1.23
ADV30
116,440
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,719,000 | -27,696,000 | 10,748,000 | 1,805,000 | 9,926,000 |
| Dec 2025 | 0 | — | -4,077,000 | -4,021,000 | 16,931,000 | 7,707,000 | 10,263,000 |
| Sep 2025 | 0 | — | -3,597,000 | -3,511,000 | 17,129,000 | 7,514,000 | 10,783,000 |
| Jun 2025 | 0 | — | -7,966,000 | -7,870,000 | 24,484,000 | 14,280,000 | 14,701,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,382,000
Investing CF
$0
Financing CF
$6,676,000
CapEx
$-18,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-46.47
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-270,072,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-43,052,000
Pretax Income TTM
$-43,098,000
Interest Exp TTM
$46,000
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,575,000 | -26,262,000 | 16,931,000 | 10,263,000 | — | -26,820,000 |
| Dec 2024 | 0 | -42,026,000 | -41,843,000 | 41,488,000 | 22,362,000 | — | -33,027,000 |
| Dec 2023 | 0 | -29,157,000 | -29,491,000 | 51,603,000 | 24,835,000 | — | -27,357,000 |
| Dec 2022 | 0 | -34,640,000 | -35,709,000 | 46,089,000 | 27,978,000 | — | -31,072,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$50,107,000
NetIncome TTM
$-38,352,000
OpCashFlow TTM
$0
Assets (Latest)
$73,238,000
Forward EPS
$-1.21
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LPCN | Lipocine Inc. | $18.63M | $2.26 | — |
| GRTX | Galera Therapeutics, Inc. | $18.70M | $0.09 | — |
| HOWL | Werewolf Therapeutics, Inc. | $18.52M | $0.38 | — |
| AEON | AEON Biopharma, Inc. | $18.81M | $0.71 | — |
| MDCX | Medicus Pharma Ltd. | $19.15M | $0.34 | — |
News headlines (Yahoo Finance, 1h cache)
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
2026-06-04 20:37 · Yahoo
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
2026-05-29 12:00 · Yahoo
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 20:15 · Yahoo
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
2026-05-06 11:00 · Yahoo
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
2026-04-29 12:00 · Yahoo
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
2026-04-22 12:00 · Yahoo
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
2026-04-14 12:00 · Yahoo
New Strong Buy Stocks for April 10th
2026-04-10 08:32 · Yahoo
Tempest Reports Year End 2025 Financial Results and Provides Business Update
2026-03-30 13:00 · Yahoo
Tempest Therapeutics Announces Up To $6 Million Private Placement
2026-03-23 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.